Claims for Patent: 11,660,304

Summary for Patent: 11,660,304

Title:	Dry powder treprostinil for the treatment of pulmonary hypertension
Abstract:	A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Inventor(s):	Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
Assignee:	Liquidia Technologies Inc
Application Number:	US17/719,439
Patent Claims:	1. A method for treating a patient having pulmonary arterial hypertension, comprising: administration of a dry powder composition comprising from about 100 micrograms to about 300 micrograms treprostinil or a pharmaceutically acceptable salt thereof to a patient by inhalation using a dry powder inhaler over one to four breaths to treat pulmonary arterial hypertension. 2. The method of claim 1, wherein the patient receives greater than about 50 micrograms treprostinil per breath. 3. The method of claim 1, wherein the dry powder composition comprises less than or equal to about 30 mg of dry powder per breath. 4. The method of claim 1, wherein the dry powder composition comprises molded dry particles comprising a non-reducing sugar, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. 5. The method of claim 1, wherein the dry powder composition comprises molded dry particles comprising by percent solids about 0.581 percent treprostinil sodium, about 92.32 percent trehalose, about 2.19 percent polysorbate 80, about 4.39 percent L-leucine, about 0.26 percent sodium citrate, and about 0.25 percent sodium chloride. 6. The method of claim 1, wherein the patient inhales the dry powder composition four times a day. 7. The method of claim 6, wherein the patient inhales a fifth dose of the dry powder composition per day. 8. The method of claim 6, wherein the patient inhales between 100 micrograms and 300 micrograms treprostinil or a pharmaceutically acceptable salt thereof through four breaths over a day. 9. The method of claim 6, wherein the patient inhales between 100 micrograms and 600 micrograms treprostinil or a pharmaceutically acceptable salt thereof through four to sixteen breaths per day. 10. A method of treating a patient having pulmonary arterial hypertension, comprising: providing a patient a dry powder inhaler; providing the patient at least one capsule for use in the dry powder inhaler, wherein the at least one capsule contains a dry powder composition comprising at least 100 micrograms of treprostinil, a non-reducing sugar, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer; and instructing the patient to utilize the dry powder inhaler to inhale the dry powder composition from each capsule in one to two breaths. 11. The method of claim 10, wherein the capsule comprises at least 150 micrograms of treprostinil. 12. A method of treating a patient having pulmonary arterial hypertension, comprising: dosing the patient having pulmonary arterial hypertension with a dry powder dose of treprostinil, wherein the dose of treprostinil is from about 100 micrograms to about 300 micrograms and delivered over one to four breaths, wherein the dry powder dose is configured into particles, wherein each particle comprises the treprostinil, a non-reducing sugar, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. 13. A method for treating a patient having pulmonary arterial hypertension, comprising: administering a dry powder composition comprising between about 400 micrograms treprostinil and about 1200 micrograms treprostinil to a patient over a day through four to sixteen breaths to treat pulmonary arterial hypertension, wherein the dry powder composition is configured as uniform particles. 14. The method of claim 13, wherein the about 400 micrograms treprostinil is inhaled by the patient in eight breaths or less per day. 15. The method of claim 13, wherein about 800 micrograms treprostinil is inhaled by the patient in eight breaths or less per day. 16. The method of claim 13, wherein about 1200 micrograms treprostinil is inhaled by the patient in sixteen breaths or less per day. 17. The method of claim 1, wherein the dry powder composition induces fewer side effects than a nebulized dose of 54 micrograms of treprostinil. 18. The method of claim 10, wherein the dry powder composition induces fewer side effects than a nebulized dose of 54 micrograms of treprostinil. 19. The method of claim 13, wherein the dry powder dose of treprostinil induces fewer side effects than a nebulized dose of 54 micrograms of treprostinil.